Adicet Bio

Q2 FY2026 EarningsQ2 FY26 results were fundamentally stronger than consensus despite a technical EPS miss: net loss of $21.4M beat the $23.7M consensus by 10.02%, while EBIT of -$22.3M exceeded the -$24.9M expectation by 10.40%. The GAAP EPS of -$1.99 missed the -$1.66 mean estimate due to a lower-than-modeled weighted average share count rather than operational underperformance. Research and development expenses decreased 35% YoY to $18.5M, reflecting significant cost discipline following strategic pipeline prioritization. With $118.2M in total cash and investments, the company maintains liquidity into H2 2027 and confirmed pivotal trial readiness for prula-cel in lupus nephritis by H2 2026.